NCT06122896View on ClinicalTrials.gov

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

5,000

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

October 31, 2040

Study Completion Date

October 31, 2041

Conditions
Pancreatic CancerPancreatic Ductal AdenocarcinomaPDACPDAC - Pancreatic Ductal AdenocarcinomaPancreatic Neoplasm
Interventions
OTHER

Screening Blood Tests

Carbohydrate antigen (CA) 19-9, and Hemoglobin A1C (HbA1c) per standard-of-care.

DIAGNOSTIC_TEST

Endoscopic Ultrasound

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

COMBINATION_PRODUCT

Magnetic Resonance Imaging

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

COMBINATION_PRODUCT

Magnetic Resonance Cholangiopancreatography

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

Trial Locations (2)

02215

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER